See more : Guangdong Songfa Ceramics Co.,Ltd. (603268.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Atossa Therapeutics, Inc. (ATOS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Atossa Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Orange Polska S.A. (PTTWF) Income Statement Analysis – Financial Results
- News World Wu Company (2245.TWO) Income Statement Analysis – Financial Results
- R.P.P. Infra Projects Limited (RPPINFRA.BO) Income Statement Analysis – Financial Results
- Rajshree Sugars and Chemicals Limited (RAJSREESUG.BO) Income Statement Analysis – Financial Results
- Bangkok Bank Public Company Limited (BBL.BK) Income Statement Analysis – Financial Results
Atossa Therapeutics, Inc. (ATOS)
About Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.76K | 525.95K | 632.56K | 481.84K | 1.50K | 0.00 | 0.00 |
| Cost of Revenue | 23.00K | 8.00K | 23.00K | 46.60K | 52.79K | 44.20K | 128.99K | 303.48K | 132.41K | 340.66K | 495.47K | 65.63K | 97.19K | 0.00 | 0.00 |
| Gross Profit | -23.00K | -8.00K | -23.00K | -46.60K | -52.79K | -44.20K | -128.99K | -303.48K | -130.65K | 185.30K | 137.09K | 416.21K | -95.69K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -7,431.91% | 35.23% | 21.67% | 86.38% | -6,379.33% | 0.00% | 0.00% |
| Research & Development | 17.33M | 15.08M | 9.21M | 6.61M | 6.65M | 4.21M | 2.33M | 770.43K | 2.36M | 2.58M | 1.11M | 1.97K | 0.00 | 120.00K | 21.25K |
| General & Administrative | 14.04M | 12.61M | 11.31M | 8.00M | 10.62M | 7.22M | 4.86M | 6.48M | 8.85M | 8.63M | 8.56M | 5.02M | 3.17M | 882.16K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.42M | 1.27M | 1.26M | 466.82K | 160.85K | 12.20K | 0.00 |
| SG&A | 14.04M | 12.61M | 11.31M | 8.00M | 10.62M | 7.22M | 4.86M | 6.48M | 10.27M | 9.90M | 9.82M | 5.49M | 3.33M | 894.36K | 101.61K |
| Other Expenses | 0.00 | -146.00K | -85.00K | 50.80K | 25.65K | 29.30K | 154.00 | 718.97K | 0.00 | 2.01M | 0.00 | 0.00 | 0.00 | 63.64K | 0.00 |
| Operating Expenses | 31.38M | 27.69M | 20.52M | 14.61M | 17.27M | 11.43M | 7.19M | 7.25M | 12.63M | 12.48M | 10.92M | 5.49M | 3.33M | 1.08M | 122.86K |
| Cost & Expenses | 31.38M | 27.69M | 20.52M | 14.61M | 17.27M | 11.43M | 7.19M | 7.25M | 12.76M | 12.82M | 11.42M | 5.55M | 3.43M | 1.08M | 122.86K |
| Interest Income | 4.34M | 877.00K | 6.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 260.00 | 295.00 | 1.22K | 4.91K | 455.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 192.82K | 0.00 | 0.00 | 15.77K | 360.00 | 12.04K | 17.99K | 9.14K | 0.00 |
| Depreciation & Amortization | 23.00K | 8.00K | 23.00K | 46.60K | 52.79K | 44.20K | 128.99K | 303.48K | 272.63K | 564.46K | 472.93K | 130.55K | 15.62K | 455.00 | 0.00 |
| EBITDA | -31.35M | -27.68M | -20.50M | -14.56M | -17.21M | -11.39M | -7.80M | -6.37M | -12.49M | -9.35M | -10.31M | -4.94M | -3.41M | -1.09M | -122.86K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -710,262.91% | -2,336.62% | -1,630.11% | -1,024.66% | -227,243.60% | 0.00% | 0.00% |
| Operating Income | -31.38M | -27.69M | -20.52M | -14.61M | -17.27M | -11.43M | -7.65M | -7.97M | -12.76M | -14.64M | -10.78M | -5.07M | -3.43M | -1.08M | -122.86K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -725,746.19% | -2,783.97% | -1,704.93% | -1,052.01% | -228,612.67% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.28M | 731.00K | -85.00K | -3.22M | 25.65K | 29.30K | -473.41K | 0.00 | 431.00 | -2.49M | -65.00 | -10.82K | -13.08K | -8.68K | 0.00 |
| Income Before Tax | -30.09M | -26.96M | -20.61M | -17.83M | -17.24M | -11.40M | -8.12M | -6.37M | -12.76M | -14.66M | -10.78M | -5.08M | -3.44M | -1.09M | -122.86K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -725,721.67% | -2,786.92% | -1,704.94% | -1,054.26% | -229,484.60% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -731.00K | -213.56K | 3.27M | -119.07K | -29.30K | 742.46K | -1.76M | 3.00M | 2.35M | 65.00 | 10.82K | 13.08K | 250.00 | 0.00 |
| Net Income | -30.09M | -26.23M | -20.61M | -21.10M | -17.24M | -11.40M | -8.12M | -6.37M | -15.76M | -14.66M | -10.78M | -5.08M | -3.44M | -1.09M | -122.86K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -896,491.64% | -2,786.92% | -1,704.94% | -1,054.26% | -229,484.60% | 0.00% | 0.00% |
| EPS | -0.24 | -0.21 | -0.18 | -1.87 | -2.03 | -2.74 | -8.33 | -25.93 | -99.79 | -109.76 | -125.37 | -73.43 | -67.96 | -32.96 | -2.42 |
| EPS Diluted | -0.24 | -0.21 | -0.18 | -1.87 | -2.03 | -2.74 | -8.33 | -25.93 | -99.79 | -109.76 | -125.37 | -73.43 | -67.96 | -32.58 | -2.42 |
| Weighted Avg Shares Out | 126.08M | 126.62M | 116.95M | 11.31M | 8.50M | 4.16M | 974.77K | 245.61K | 157.93K | 133.55K | 86.02K | 69.18K | 50.65K | 32.98K | 50.77K |
| Weighted Avg Shares Out (Dil) | 126.08M | 126.62M | 116.95M | 11.31M | 8.50M | 4.16M | 974.77K | 245.61K | 157.93K | 133.55K | 86.02K | 69.18K | 50.65K | 33.36K | 50.77K |
Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research
Highlights Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds in ERα+ Breast Cancer Highlights Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds in ERα+ Breast Cancer
Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium
Detailed results from the KARISMA-Endoxifen trial demonstrating (Z)-endoxifen's ability to significantly reduce mammographic breast density to be featured at conference Detailed results from the KARISMA-Endoxifen trial demonstrating (Z)-endoxifen's ability to significantly reduce mammographic breast density to be featured at conference
Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
SEATTLE, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced financial results for the fiscal quarter ended September 30, 2024, and provided...
Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development
Dr. Lopez Brings 20+ Years of Global Clinical Development and Leadership to Support Atossa's Mission in Developing Innovative Breast Cancer Therapies Dr. Lopez Brings 20+ Years of Global Clinical Development and Leadership to Support Atossa's Mission in Developing Innovative Breast...
Atossa Therapeutics Reports Positive KARISMA-Endoxifen Trial Results:
(Z)-Endoxifen Shown to Significantly Reduce Mammographic Breast Density, Potentially Paving the Way for Innovative Cancer Prevention Strategies
Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen's Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer
(Z)-endoxifen at 10 mg once daily met the primary endpoint with 19/20 (95%) receiving > 75 % of planned treatment in I-SPY-2 Phase 2 Trial
Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year?
Here is how Atossa Genetics Inc. (ATOS) and Cardinal Health (CAH) have performed compared to their sector so far this year.
Atossa Therapeutics to Participate in Fireside Chat with Karolinska Institute at BIO-EUROPE 2024 to Discuss a Unique Swedish American Collaboration to Prevent Breast Cancer
SEATTLE, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ: ATOS) (“Atossa” or the “Company”), today announced that Steven Quay, M.D., Ph.D., Chairman and Chief Executive Officer, will join Per Hall, M.D., Professor of Epidemiology at the Department of...
Atossa Therapeutics to Present at the 2024 Maxim Healthcare Virtual Summit
SEATTLE, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that Michael Parks, Vice President, Investor and Public Relations, will participate in a virtual fireside chat on Wednesday, October 16, 2024 at 12:00...
Atossa Therapeutics Commemorates Breast Cancer Awareness Month, Highlighting the Need for Innovation Across the Breast Cancer Treatment Continuum
SEATTLE, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), today announced its recognition and support of Breast Cancer Awareness Month this October; highlighting the importance of increasing awareness, advancing research, and driving progress...
Source: https://incomestatements.info
Category: Stock Reports